{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:39:21Z","timestamp":1787974761303,"version":"build-2784847793"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamaneurol.2018.0278","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T12:31:55Z","timestamp":1522672315000},"page":"842","source":"Crossref","is-referenced-by-count":63,"title":["Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population"],"prefix":"10.1001","volume":"75","author":[{"given":"Taisei","family":"Mushiroda","sequence":"first","affiliation":[{"name":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiichi","family":"Onuma","sequence":"additional","affiliation":[{"name":"Musashino-Kokubunji Clinic, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsumasa","family":"Kamei","sequence":"additional","affiliation":[{"name":"Tokushukai Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hoshida","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nara Medical Center, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Iwate Medical University, Iwate, Japan"},{"name":"Kitariasu Hospital, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Iwate Medical University, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kanemoto","sequence":"additional","affiliation":[{"name":"Neuropsychiatric Department, Aichi Medical University, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Oshima","sequence":"additional","affiliation":[{"name":"Neuropsychiatric Department, Aichi Medical University, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Personalized Genetic Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Minami","sequence":"additional","affiliation":[{"name":"Institute for Advanced Medical Sciences, Nippon Medical School, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Saito","sequence":"additional","affiliation":[{"name":"Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tanii","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mie University Graduate School of Medicine, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hara","sequence":"additional","affiliation":[{"name":"Hara Clinic, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saitoh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Occupational and Environmental Health, Kitakyusyu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Fukuchi","sequence":"additional","affiliation":[{"name":"Suzukake Clinic, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yasumoto","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ozeki","sequence":"additional","affiliation":[{"name":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Izumida","sequence":"additional","affiliation":[{"name":"Department of Empirical Social Security Research, National Institute of Population and Social Security Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shiohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Kubo","sequence":"additional","affiliation":[{"name":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GENCAT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1-2","key":"noi180012r1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12016-007-8010-9","article-title":"A complex interaction between drug allergy and viral infection.","volume":"33","author":"Shiohara","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9308","key":"noi180012r2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"noi180012r3","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"noi180012r4","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1038\/srep04862","article-title":"Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"issue":"2","key":"noi180012r5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"noi180012r6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2016.234","article-title":"Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.","volume":"16","author":"Giacomini","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"noi180012r7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response.","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"noi180012r8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00004714-199412000-00006","article-title":"Rash complicating carbamazepine treatment.","volume":"14","author":"Kramlinger","year":"1994","journal-title":"J Clin Psychopharmacol"},{"issue":"20","key":"noi180012r9","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","article-title":"Comparison and predictors of rash associated with 15 antiepileptic drugs.","volume":"68","author":"Arif","year":"2007","journal-title":"Neurology"},{"issue":"12","key":"noi180012r10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"noi180012r11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0404.2011.01553.x","article-title":"Comparison of carbamazepine rash in multiple sclerosis and epilepsy.","volume":"125","author":"Shirzadi","year":"2012","journal-title":"Acta Neurol Scand"},{"issue":"6982","key":"noi180012r12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome.","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"4","key":"noi180012r13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"noi180012r14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","article-title":"HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.","volume":"92","author":"Yip","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"noi180012r15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"noi180012r16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"20","key":"noi180012r17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"noi180012r18","doi-asserted-by":"crossref","first-page":"e62989","DOI":"10.1371\/journal.pone.0062989","article-title":"A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.","volume":"8","author":"Kitano","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"noi180012r19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/FPC.0b013e3283527c40","article-title":"New pharmacogenetic test for detecting an HLA-A*31:01 allele using the InvaderPlus assay.","volume":"22","author":"Aoki","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"3S","key":"noi180012r20","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.je.2016.12.005","article-title":"Overview of the BioBank Japan project: study design and profile.","volume":"27","author":"Nagai","year":"2017","journal-title":"J Epidemiol"},{"issue":"3S","key":"noi180012r21","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.je.2016.12.003","article-title":"Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 common diseases.","volume":"27","author":"Hirata","year":"2017","journal-title":"J Epidemiol"},{"issue":"1","key":"noi180012r23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","article-title":"Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.","volume":"27","author":"Kurose","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"noi180012r24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/tan.12536","article-title":"Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study.","volume":"85","author":"Ikeda","year":"2015","journal-title":"Tissue Antigens"},{"issue":"3","key":"noi180012r25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"noi180012r26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","article-title":"HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population.","volume":"39","author":"Niihara","year":"2012","journal-title":"J Dermatol"},{"issue":"6","key":"noi180012r27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2042098613499791","article-title":"The risk of cutaneous adverse reactions among patients with the HLA-A*31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review.","volume":"4","author":"Kaniwa","year":"2013","journal-title":"Ther Adv Drug Saf"},{"issue":"1-2","key":"noi180012r28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"issue":"1","key":"noi180012r29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children.","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"noi180012r30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/epi.12937","article-title":"Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.","volume":"56","author":"Plumpton","year":"2015","journal-title":"Epilepsia"},{"issue":"6","key":"noi180012r32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir.","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"noi180012r33","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"noi180012r22","unstructured":"Japan Medical Data Center. JMDC claims database. https:\/\/www.jmdc.co.jp\/en\/pharma\/database.html. Accessed May 1, 2017."},{"key":"noi180012r31","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword. Accessed November 1, 2016."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2676800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T12:33:25Z","timestamp":1531139605000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.0278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.0278","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}